Sickle cell care plan choices for teens and young adults
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This trial tests a way to help teens and young adults with sickle cell disease (SCD) and their caregivers actively take part in treatment decisions. It focuses on improving shared decision-making through interviews and a partner-centered approach.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 15 to 25 years old and have sickle cell disease (SCD)
- Currently receive SCD care at Nemours
- Your SCD clinician thinks you may be ready to start a disease-modifying treatment (or treatments)
- You and your caregiver can complete things in English
- You (and your caregiver, if relevant) have not already joined usability testing for this same program
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a computer-based “attention control” training program can improve attention and daily functioning in children with sickle cell disease. To join, you must meet certain criteria and also pass an initial attention screening test during the study.
This study tests a structured program to help teens with sickle cell disease smoothly transition from pediatric care to adult care, with support for parents or legal guardians. It may help families coordinate care sooner and more confidently during this change.
This trial tests a new treatment called CS-206 for adolescents with severe sickle cell disease. It aims to see if this treatment can help by making stem cell transplants safer and more effective for people who have not done well with standard care.
This Phase 2 study tests a cognitive (thinking) training program to help teens with sickle cell disease prepare for the changes in their care as they grow older. It may help with skills like learning, attention, and planning for transition to adult care.
This study collects feedback through surveys, interviews, and focus groups from people affected by sickle cell disease. Your input helps the research team improve how genomic and gene-therapy information and needs are understood for patients and caregivers.
This study uses one-on-one interviews to learn what families and clinicians need to make decisions about gene therapy for rare diseases. The goal is to create or improve decision tools that make gene therapy information easier to understand and act on.
Hear when a new Sickle Cell Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.